To identify biopsychosocial factors associated with opioid use for neuropathic pain in adults with SCI. We studied 283 adults with SCI who were enrolled in a…
Cannabinoids Show Promise for Chronic Pain, But Evidence Remains Thin – CED Clinic
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Chronic PainNeuropathic PainEvidence-Based MedicinePain ManagementClinical Practice Why This MattersChronic pain affects over 50 million...
Assessments of Evoked and Spontaneous Pain Following Administration of Gabapentin and the Cannabinoid CB
Cannabinoid CB We compared the impact of LY2828360 on evoked and spontaneous pain in a spared nerve injury (SNI) model using a within-subjects design in rats…
Cannabis-based interventions might help a little with neuropathic pain – Study Summary
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Neuropathic PainPain ManagementCannabinoidsChronic PainEvidence Review Why This MattersNeuropathic pain affects millions of patients...
Honoring the trailblazers with MS who changed cannabis policy – Blog
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Multiple SclerosisSpasticityMedical Cannabis PolicyPatient AdvocacyNeuropathic Pain Why This MattersMultiple sclerosis patients were among the...
Opioids and Cannabinoids for Neurologic Pain: What Neurologists Need to Know in 2024
Subsequent studies documented how the tapering and discontinuation of long-term opioid therapy was correlated with illicit opioid use, emergency department visits and opioid-related hospitalizations, mental health crises and overdose events, and increased risk of death from suicide or overdose.
Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
Neurocutaneous dysesthesia (ND) is characterized by abnormal skin sensations such as pruritus or burning without an underlying skin condition. It is caused b…
Targeting molecular pathways in neuropathic cancer pain: from mechanisms to novel therapeutics.
Neuropathic cancer pain (NCP) remains a formidable clinical adversary, severely compromising the quality of life for cancer survivors. Its pathogenesis is hi…
Cannabis-based medicines for chronic neuropathic pain in adults.
Estimates of the population prevalence of chronic pain with neuropathic components range from 6% to 10%. Current pharmacological treatments for neuropathic p…
Cannabis Oil Did Not Meaningfully Reduce Pain in Nerve-Injury Patients, Rigorous Trial Finds
Our study findings indicate that cannabis-based medicine did not improve pain by a clinically important margin. Consequently, our study advises against the addition of cannabis-based medicine to the standard medication treatment for pain in patients with traumatic brachial plexus injury.